AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12620132 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 12620132 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 12620132 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 0
Study 12620132 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 0
Study 12620132 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium‐channel blocker verapamil
Number of subjects: 0
Study 14505192 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 0
Study 10759055 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical orientation towards attachment
Number of subjects: 64
Study 10759055 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measure of theoretical orientation
Number of subjects: 64
Study 10759055 — intervention group
Group type: COMPARATOR
Intervention: Availability bias due to suggestion in referral letter
Number of subjects: 64
Study 10759055 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical orientation
Number of subjects: 64
Study 8648358 — intervention group
Group type: EXPERIMENTAL
Intervention: HFX RT with 1.2 Gy twice daily to a total dose of 69.6 Gy (n = 66)
Number of subjects: 131
Study 8648358 — intervention group
Group type: COMPARATOR
Intervention: HFX RT with CHT consisting of 50 mg of carboplatin and 50 mg of etoposide given on each RT day (n = 65)
Number of subjects: 131
Study 1626664 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid hyperbaric bupivacaine 15 mg with 50 micrograms of fentanyl (group A)
Number of subjects: 28
Study 1626664 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid hyperbaric bupivacaine 15 mg with 25 micrograms of fentanyl (group B)
Number of subjects: 28
Study 1626664 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid hyperbaric bupivacaine 15 mg with 12.5 micrograms of fentanyl (group C)
Number of subjects: 28
Study 1626664 — intervention group
Group type: COMPARATOR
Intervention: 1 ml of saline (group D)
Number of subjects: 28
Study 6375243 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation
Number of subjects: 25
Study 6375243 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 25
Study 2437837 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg)
Number of subjects: 9
Study 2437837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous)
Number of subjects: 9
Study 30659901 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-clamp robot-assisted partial nephrectomy
Number of subjects: 80
Study 30659901 — intervention group
Group type: COMPARATOR
Intervention: On-clamp robot-assisted partial nephrectomy
Number of subjects: 80
Study 28382618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.6 mg/m2 intravenously on days 1, 8, 15, and 22 for four 35-day cycles
Number of subjects: 104
Study 28382618 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 104
Study 26437422 — intervention group
Group type: EXPERIMENTAL
Intervention: ProfScreen intervention (screening program)
Number of subjects: 1007
Study 26437422 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency procedure for suicidal students
Number of subjects: 1007
Study 26437422 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of clinician’s motivations
Number of subjects: 1007
Study 23647281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based behavior therapy (ABBT)
Number of subjects: 81
Study 23647281 — intervention group
Group type: COMPARATOR
Intervention: Applied relaxation (AR)
Number of subjects: 81
Study 23647281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (ABBT and AR)
Number of subjects: 81
Study 23647281 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 81
Study 20809177 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal gastrectomy
Number of subjects: 211
Study 20809177 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy
Number of subjects: 211
Study 20809177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving gastrectomy
Number of subjects: 211
Study 20809177 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumed activities
Number of subjects: 211
Study 20809177 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced activities
Number of subjects: 211
Study 20809177 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal activities
Number of subjects: 211
Study 20809177 — intervention group
Group type: EXPERIMENTAL
Intervention: Did not resume activities due to poor physical condition
Number of subjects: 211
Study 19274056 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 27
Study 19274056 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet, exercise and acupuncture
Number of subjects: 27
Study 19274056 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 19274056 — intervention group
Group type: COMPARATOR
Intervention: Changes in lean body mass
Number of subjects: 27
Study 16482646 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg administered twice weekly
Number of subjects: 77
Study 16482646 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 25 mg administered twice weekly
Number of subjects: 77
Study 15262358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid hystroscopy
Number of subjects: 30
Study 15262358 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 11382520 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated EMS transport stress (n = 16)
Number of subjects: 32
Study 11382520 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 32
Study 9404860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (F(I)O2 0.622)
Number of subjects: 6
Study 9404860 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (F(I)O2 0.209)
Number of subjects: 6
Study 9404860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (F(I)O2 0.158)
Number of subjects: 6
Study 8127928 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (81 patients, 100-300 mg/day)
Number of subjects: 160
Study 8127928 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine (79 patients, 10-30 mg/day)
Number of subjects: 160
Study 8127928 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 160
Study 8127928 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 160
Study 3038552 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood from donors without detectable CMV antibodies (CMV seronegative blood)
Number of subjects: 34
Study 3038552 — intervention group
Group type: COMPARATOR
Intervention: Blood from unselected donors
Number of subjects: 34
Study 29202885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 197
Study 29202885 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 197
Study 28587620 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg per day)
Number of subjects: 40
Study 28587620 — intervention group
Group type: COMPARATOR
Intervention: Methadone (40 mg per day)
Number of subjects: 40
Study 26223309 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecoaching plus portion control plate
Number of subjects: 90
Study 26223309 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study 23017529 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic assisted laparoscopic radical cystectomy
Number of subjects: 47
Study 23017529 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 47
Study 21169634 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at pericardium 6 bilaterally, depth of approximately 0.7 cm, median duration of 21 min during anaesthesia, followed by acupressure wristbands for 24 h and standard treatment.
Number of subjects: 154
Study 21169634 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 154
Study 18268152 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 and 0.2 microg x kg(‐1) x min(‐1))
Number of subjects: 23
Study 18268152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16948927 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1 mg/day for 6 months)
Number of subjects: 40
Study 16948927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14503797 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin (11.25 mg s.c. every 3 months for 2 years)
Number of subjects: 133
Study 14503797 — intervention group
Group type: COMPARATOR
Intervention: CMF chemotherapy (6 cycles)
Number of subjects: 133
Study 11154141 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol plus 1 mg norethisterone acetate, 1 tablet daily (HRT group)
Number of subjects: 140
Study 11154141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 140
Study 10895224 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (TD)
Number of subjects: 60
Study 10895224 — intervention group
Group type: COMPARATOR
Intervention: Bicycle ergometer exercise (BE)
Number of subjects: 60
Study 10895224 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise on BE
Number of subjects: 60
Study 10895224 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise on TD
Number of subjects: 60
Study 10895224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of perceived exertion
Number of subjects: 60
Study 10895224 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for exercise mode
Number of subjects: 60
Study 8320925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane
Number of subjects: 9
Study 8320925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose acetate
Number of subjects: 9
Study 8320925 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate
Number of subjects: 9
Study 8320925 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulphone
Number of subjects: 9
Study 8320925 — intervention group
Group type: EXPERIMENTAL
Intervention: AN-69
Number of subjects: 9
Study 3091543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (home-based nutrition counselling sessions for mothers/caretakers)
Number of subjects: 65
Study 3091543 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 65
Study 3091543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 65
Study 30172995 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid intake (2.7 g/d for 6 weeks)
Number of subjects: 54
Study 30172995 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 54
Study 28432157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 117
Study 28432157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 26310452 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based CPAP follow-up strategy
Number of subjects: 139
Study 26310452 — intervention group
Group type: COMPARATOR
Intervention: Standard face-to-face management
Number of subjects: 139
Study 23430390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR) at a starting dose of 12 mg/kg/day
Number of subjects: 35
Study 23430390 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) at a starting dose of 2 g/day
Number of subjects: 35
Study 20690864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg oral conjugated estrogens for 30 days
Number of subjects: 40
Study 20690864 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 40
Study 19699856 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based care approach
Number of subjects: 0
Study 19699856 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promotion campaign
Number of subjects: 0
Study 16916335 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus structured education on the use of a written self-management plan and patient-initiated short courses of antibiotics and oral corticosteroids
Number of subjects: 159
Study 16916335 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 159
Study 15315625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg IM and normal saline IV
Number of subjects: 88
Study 15315625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg IM and tenoxicam 40 mg IV
Number of subjects: 88
Study 15315625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg IV
Number of subjects: 88
Study 15315625 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine maleate (CPM) 20 mg IM and normal saline IV
Number of subjects: 88
Study 11011670 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 84
Study 11011670 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (non-operated group)
Number of subjects: 84
Study 9076589 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis-targeted quality of life questionnaire (OPTQoL)
Number of subjects: 465
Study 9076589 — intervention group
Group type: COMPARATOR
Intervention: Standard generic questionnaire (SF-36)
Number of subjects: 465
Study 8361796 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 689
Study 8361796 — intervention group
Group type: COMPARATOR
Intervention: Conditioning alarms
Number of subjects: 689
Study 2871788 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month regimen of chemotherapy (streptomycin, isoniazid, rifampin, pyrazinamide for 2 months followed by isoniazid and rifampin)
Number of subjects: 330
Study 2871788 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month regimen of chemotherapy (streptomycin, isoniazid, rifampin, pyrazinamide for 2 months followed by isoniazid and rifampin)
Number of subjects: 330
Study 2871788 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bacilli resistant to isoniazid, streptomycin, or both drugs in the 6-month series
Number of subjects: 330
Study 2871788 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bacilli resistant to isoniazid, streptomycin, or both drugs in the 4-month series
Number of subjects: 330
Study 28822586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (12.5g)
Number of subjects: 199
Study 28822586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 26921492 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline chest pain
Number of subjects: 384
Study 26921492 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbness/tingling
Number of subjects: 384
Study 26921492 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms (Patient Health Questionnaire-9)
Number of subjects: 384
Study 26921492 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher comorbidity count
Number of subjects: 384
Study 25379847 — intervention group
Group type: EXPERIMENTAL
Intervention: NCRT
Number of subjects: 593
Study 25379847 — intervention group
Group type: COMPARATOR
Intervention: Primary Surgery
Number of subjects: 593
Study 21963681 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education group sessions (6 during pregnancy, 1 after childbirth)
Number of subjects: 355
Study 21963681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 355
Study 20597857 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-enhanced laboratory
Number of subjects: 53
Study 20597857 — intervention group
Group type: COMPARATOR
Intervention: Traditional laboratory
Number of subjects: 53
Study 17606671 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-lying external rotation
Number of subjects: 45
Study 17606671 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-lying forward flexion
Number of subjects: 45
Study 17606671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone horizontal abduction with external rotation
Number of subjects: 45
Study 17606671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone extension
Number of subjects: 45
Study 17606671 — intervention group
Group type: COMPARATOR
Intervention: None of the exercises
Number of subjects: 45
Study 15822041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplement enriched with fish oil, fructooligosaccharides, gum arabic, vitamin E, vitamin C, and selenium, 18 oz daily for 6 months
Number of subjects: 121
Study 15822041 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-based placebo formula, 18 oz daily for 6 months
Number of subjects: 121
Study 12402011 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of the palate (RFAP)
Number of subjects: 20
Study 12402011 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted uvulopalatoplasty (LAUP)
Number of subjects: 20
Study 10192404 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 339
Study 10192404 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 339
Study 10192404 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Olanzapine and Risperidone
Number of subjects: 339
Study 8520812 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine with naltrexone
Number of subjects: 0
Study 1996763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 10 mg
Number of subjects: 273
Study 1996763 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine 10 mg
Number of subjects: 273
Study 1996763 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline 0.5 ml (Control)
Number of subjects: 273
Study 6853080 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion
Number of subjects: 202
Study 30478089 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation (haplo‐HSCT)
Number of subjects: 147
Study 30478089 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 147
Study 30354627 — intervention group
Group type: EXPERIMENTAL
Intervention: NuMED Covered CP Stent (CCPS)
Number of subjects: 120
Study 25045806 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted vaccine
Number of subjects: 84
Study 25045806 — intervention group
Group type: COMPARATOR
Intervention: Adjuvanted vaccine
Number of subjects: 84
Study 22334769 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg
Number of subjects: 1196
Study 22334769 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 200/10 μg
Number of subjects: 1196
Study 22334769 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 400 μg
Number of subjects: 1196
Study 22334769 — intervention group
Group type: COMPARATOR
Intervention: Formoterol (F) 10 μg
Number of subjects: 1196
Study 22334769 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F)
Number of subjects: 1196
Study 22334769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1196
Study 19179917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresorbable poly-ether-ether-ketone (PEEK) cage
Number of subjects: 26
Study 19179917 — intervention group
Group type: COMPARATOR
Intervention: Resorbable poly-L-lactide-co-D,L-lactide (PLDLLA) cage
Number of subjects: 26
Study 17690198 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-alanine (4.8 g/day)
Number of subjects: 15
Study 17690198 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 15383109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 80
Study 15383109 — intervention group
Group type: COMPARATOR
Intervention: Bupivicaine/Fentanyl
Number of subjects: 80
Study 11420346 — intervention group
Group type: EXPERIMENTAL
Intervention: HandClens (alcohol-free antiseptic hand wash)
Number of subjects: 40
Study 11420346 — intervention group
Group type: COMPARATOR
Intervention: Purell (alcohol-based product)
Number of subjects: 40
Study 9043028 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin 3 (rhIL‐3) 10 microg kg(‐1) day(‐1) (days 5‐9) + G‐CSF 5.0 microg kg(‐1) day(‐1) (days 7‐16)
Number of subjects: 16
Study 9043028 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg m(‐2) day 1), ifosfamide (1.2 g m(‐2) day(‐1) days 2-4), cisplatin (30 mg m(‐2) day(‐1) days 2-4) + G‐CSF 5.0 microg kg(‐1) day(‐1) (days 7-16)
Number of subjects: 16
Study 7639381 — intervention group
Group type: COMPARATOR
Intervention: Normal saline IV and epidurally (Control Group A)
Number of subjects: 60
Study 7639381 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of 2% lidocaine IV as a bolus (Group B)
Number of subjects: 60
Study 7639381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of 2% lidocaine IV for 5 min (Group C)
Number of subjects: 60
Study 7639381 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of 2% lidocaine IV for 5 min (Group D)
Number of subjects: 60
Study 7639381 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of 1.5% lidocaine epidurally as a bolus (Group E)
Number of subjects: 60
Study 3235818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 12
Study 3235818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem (50 mg)
Number of subjects: 12
Study 3235818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem (25 mg)
Number of subjects: 12
Study 3235818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol + Lorazepam
Number of subjects: 12
Study 3235818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol + Alpidem (50 mg)
Number of subjects: 12
Study 3235818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol + Alpidem (25 mg)
Number of subjects: 12
Study 3235818 — intervention group
Group type: COMPARATOR
Intervention: Alcohol + Placebo
Number of subjects: 12
Study 29893482 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDiPORT cognitive-behavioral arm (robot using evidence-based cognitive-behavioral interventions)
Number of subjects: 40